3rd Annual Jefferson Urology Symposium: Men’s Health Forum

© The Canadian Journal of Urology TM : International Supplement, August 2020 19 Peyronie’s disease: what do we know and how do we treat it? 22. Inal T, Tokatli Z, Akand M, Ozdiler E, Yaman O. Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie’s disease: a randomized and prospective study. Urology 2006;67(5):1038-1042. 23. Hellstrom WJ, Kendirci M, Matern R et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie’s disease. J Urol 2006;176(1):394-398. 24. Trost LW, Ates E, Powers M, Sikka S, Hellstrom WJ. Outcomes of intralesional interferon- α 2B for the treatment of Peyronie disease. J Urol 2013;190(6):2194-2199. 25. Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie’sdisease. JUrol 1994;151(6):1522-1524. 26. Levine LA, Goldman KE, Greenfield JM. Experience with intraplaque injection of verapamil for Peyronie’s disease. J Urol 2002;168(2):621-625; discussion 625-626. 27. Arena F, PeracchiaG, Di StefanoC, PassariA, LarosaM, Cortellini P. [Clinical effects of verapamil in the treatment of Peyronie’s disease]. Acta Biomed Ateneo Parmense 1995;66(6):269-272. 28. Palmieri A, Imbimbo C, Longo N et al. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shockwave therapy for the treatment of Peyronie’s disease. Eur Urol 2009;56(2):363-369. 29. Palmieri A, Imbimbo C, Creta M, Verze P, Fusco F, Mirone V. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie’s disease and erectile dysfunction: results from a prospective randomized trial. Int J Androl 2012;35(2):190-195. 30. HatzichristodoulouG,Meisner C, Gschwend JE, StenzlA, Lahme S. Extracorporeal shock wave therapy in Peyronie’s disease: results of a placebo-controlled, prospective, randomized, single- blind study. J Sex Med 2013;10(11):2815-2821. 31. Chitale S, Morsey M, Swift L, Sethia K. Limited shock wave therapy vs sham treatment in men with Peyronie’s disease: results of a prospective randomized controlled double-blind trial. BJU Int 2010;106(9):1352-1356. 32. Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration for Peyronie’s disease: a double-blind, placebo controlled trial. J Urol 2007;177(3):972-975. 33. Di Stasi SM, Giannantoni A, Stephen RL et al. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie’s disease. J Urol 2004;171(4):1605-1608. 34. Levine LA, Newell MM. FastSize medical extender for the treatment of Peyronie’s disease. Expert Rev Med Devices 2008;5(3):305-310. 35. Gontero P, Di Marco M, Giubilei G et al. Use of penile extender device in the treatment of penile curvature as a result of Peyronie’s disease. Results of a phase II prospective study. J Sex Med 2009;6(2):558-566. 36. Martínez-Salamanca JI, Egui A, Moncada I et al. Acute phase Peyronie’s disease management with traction device: a nonrandomized prospective controlled trial with ultrasound correlation. J Sex Med 2014;11(2):506-515. 37. ZiegelmannM, Savage J, ToussiAet al. Outcomes of a novel penile traction device in men with Peyronie’s disease: a randomized, single-blind, controlled trial. J Urol 2019;202(3):599-610. 38.Wymer K, Kohler T, Trost L. Comparative cost-effectiveness of surgery, collagenase clostridium histolyticum, and penile traction therapy in men with Peyronie’s disease in an era of effective clinical treatment. J Sex Med 2019;16(9):1421-1432. 39. Gholami SS, Lue TF. Correction of penile curvature using the 16-dot plication technique: a review of 132 patients. J Urol 2002;167(5):2066-2069. 40. Adibi M, Hudak SJ, Morey AF. Penile plication without degloving enables effective correction of complex Peyronie’s deformities. Urology 2012;79(4):831-835. 41. Chung PH, Tausch TJ, Simhan J, Scott JF, Morey AF. Dorsal plication without degloving is safe and effective for correcting ventral penile deformities. Urology 2014;84(5):1228-1233. 42. Chung E, Clendinning E, Lessard L, Brock G. Five-year follow-up of Peyronie’s graft surgery: outcomes and patient satisfaction. J Sex Med 2011;8(2):594-600. 43.Wimpissinger F, Parnham A, Gutjahr G, Maksys S, Baierlein M, StacklW. 10 years’ plaque incision andveingrafting for Peyronie’s disease: does time matter? J Sex Med 2016;13(1):120-128. 44. Da Ros CT, Graziottin TM, Ribeiro E, AverbeckMA. Long-term follow-up of penile curvature correction utilizing autologous albugineal crural graft. Int Braz J Urol 2012;38(2):242-247; discussion 248-249. 45. Sansalone S, Garaffa G, Djinovic R et al. Long-term results of the surgical treatment of Peyronie’s disease with Egydio’s technique: a European multicentre study. Asian J Androl 2011;13(6):842-845. 46. Kim DH, Lesser TF, Aboseif SR. Subjective patient-reported experiences after surgery for Peyronie’s disease: corporeal plication versus plaque incision with vein graft. Urology 2008;71(4):698-702. 47. Khera M, Bella A, Karpman E et al. Penile prosthesis implantation in patients with Peyronie’s disease: results of the PROPPER study demonstrates a decrease in patient-reported depression. J Sex Med 2018;15(5):786-788. 48. Levine LA, Benson J, Hoover C. Inflatable penile prosthesis placement in men with Peyronie’s disease and drug- resistant erectile dysfunction: a single-center study. J Sex Med 2010;7(11):3775-3783. 49.Wilson SK, Delk JR 2 nd . Anew treatment for Peyronie’s disease: modeling the penis over an inflatable penile prosthesis. J Urol 1994;152(4):1121-1123. 50. RahmanNU, Carrion RE, Bochinski D, Lue TF. Combined penile plication surgery and insertion of penile prosthesis for severe penile curvature and erectile dysfunction. J Urol 2004;171(6 Pt 1):2346-2349. 51. Cormio L, Massenio P, Di Fino G et al. Long-term results of combined tunica albuginea plication and penile prosthesis implantation for severe penile curvature and erectile dysfunction. Case Rep Urol 2014;2014:818623. 52. Chung PH, Scott JF, Morey AF. High patient satisfaction of inflatable penile prosthesis insertion with synchronous penile plication for erectile dysfunction and Peyronie’s disease. J Sex Med 2014;11(6):1593-1598. 53. Djordjevic ML, Kojovic V. Penile prosthesis implantation and tunica albuginea incision without grafting in the treatment of Peyronie’s disease with erectile dysfunction. Asian J Androl 2013;15(3):391-394. 54. Tausch TJ, Chung PH, Siegel JA, Gliga L, Klein AK, Morey AF. Intraoperative decision-making for precise penile straightening during inflatable penile prosthesis surgery. Urology 2015;86(5):1048-1052. 55. Raheem AA, Garaffa G, Raheem TA et al. The role of vacuum pump therapy tomechanically straighten the penis in Peyronie’s disease. BJU Int 2010;106(8):1178-1180. 56. Matz EL, Pearlman AM, Terlecki RP. Safety and feasibility of platelet rich fibrin matrix injections for treatment of common urologic conditions. Investig Clin Urol 2018;59(1):61-65. 57. Castiglione F, Hedlund P, Van derAa et al. Intratunical injection of human adipose tissue-derived stemcells prevents fibrosis and is associated with improved erectile function in a rat model of Peyronie’s disease. Eur Urol 2013;63(3):551-560. 58. Gokce A, Abd Elmageed ZY, Lasker GF et al. Intratunical injection of genetically modified adipose tissue-derived stem cells with human interferon α -2b for treatment of erectile dysfunction in a rat model of tunica albugineal fibrosis. J Sex Med 2015;12(7):1533-1544.